![]()
Palatin to Report First Quarter Fiscal Year 2027 Results
PR Newswire
PRINCETON, N.J., Nov. 13, 2026
Teleconference and Webcast to be held on November 17, 2026
PRINCETON, N.J., Nov. 13, 2026 /PRNewswire/ — Palatin Technologies, Inc. (Nasdaq: PTN) will announce its first quarter fiscal year 2027 operating results on Tuesday, November 17, 2026, before the open of the U.S. financial markets.
Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 17, 2026, at 11:00 a.m. ET. The conference call will provide an update on corporate and development activities.
Schedule for the Operating Results Press Release, Conference Call / Audio Webcast
|
Q1 Fiscal Year 2027 Results Press Release |
11/17/2026 at 7:30 a.m. ET |
|
Q1 Fiscal Year 2027 Conference Call-Live |
11/17/2026 at 11:00 a.m. ET |
|
US Toll Free Dial-In Number: |
1-888-506-0062 |
|
International Dial-In Number: |
1-973-528-0011 |
|
Participant Access Code: |
336522 |
|
Q1 Fiscal Year 2027 Conference Call-Replay |
11/17/2026-12/01/2026 |
|
US Toll Free Dial-In Number: |
1-877-481-4010 |
|
International Dial-In Number: |
1-919-882-2331 |
|
Replay Passcode: |
54837 |
The audio webcast and replay can be accessed by logging on to the “Investors-Webcasts” section of Palatin’s website at http://www.palatin.com or by clicking here.
About Palatin
Palatin Technologies, Inc. is a biopharmaceutical company developing medicines targeting the melanocortin receptor system. Palatin’s principal strategic development focus is advancing next-generation MC4R-selective agonists for rare neuroendocrine obesity disorders, including hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome. The Company is developing long-acting injectable peptide agonists, oral small-molecule agonists and an oral peptide agonist approach, with the objective of delivering differentiated efficacy, tolerability and dosing profiles suitable for long-term treatment. Palatin also utilizes collaborations, licensing arrangements and strategic partnerships to advance other melanocortin-based programs. For more information, visit www.palatin.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/palatin-to-report-first-quarter-fiscal-year-2027-results-302938488.html
SOURCE Palatin Technologies, Inc.
